as 07-26-2024 4:00pm EST
SIGA Technologies Inc is a commercial-stage pharmaceutical company focused on the health security market. The company's main product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by the variola virus. The company derives maximum revenue from United States.
Upcoming Earnings Alert:
Get ready for potential market movements as SIGA Technologies Inc. SIGA prepares to release earnings report on 01 Aug 2024.
Founded: | 1995 | Country: | United States |
Employees: | N/A | City: | NEW YORK |
Market Cap: | 455.9M | IPO Year: | 1997 |
Target Price: | N/A | AVG Volume (30 days): | 502.4K |
Analyst Decision: | N/A | Number of Analysts: | N/A |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | 1.10 | EPS Growth: | 139.13 |
52 Week Low/High: | $4.22 - $10.83 | Next Earning Date: | 08-01-2024 |
Revenue: | $157,024,051 | Revenue Growth: | 44.64% |
Revenue Growth (this year): | 29.44% | Revenue Growth (next year): | -8.96% |
SIGA Breaking Stock News: Dive into SIGA Ticker-Specific Updates for Smart Investing
GlobeNewswire
2 days ago
Zacks
2 days ago
Pharmaceutical Technology
4 days ago
MT Newswires
8 days ago
GlobeNewswire
8 days ago
Zacks
8 days ago
Zacks
15 days ago
Zacks
18 days ago
The information presented on this page, "SIGA SIGA Technologies Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.